Last reviewed · How we verify
Peripheral vascular disease
Approved treatments
- Ilidar
Ilidar works by inhibiting platelet aggregation, which helps to improve blood flow and reduce the risk of blood clots. - Barbonin
Barbonin works by improving blood flow to the affected areas of the body. - Brilinta · AstraZeneca
- Brilinta · AstraZeneca
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Peripheral vascular disease patent landscape — cliff calendar, originator estates, attackable patents
- Peripheral vascular disease treatment landscape brief
- Peripheral vascular disease treatment updates RSS
Frequently asked questions about Peripheral vascular disease
What drugs treat Peripheral vascular disease?
Tracked treatments include Ilidar, Barbonin, Brilinta.
What is the treatment for Peripheral vascular disease?
Standard treatment for Peripheral vascular disease includes Ilidar, Barbonin, Brilinta. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Peripheral vascular disease patent cliff · Peripheral vascular disease CI report
- Treatment: Ilidar
- Treatment: Barbonin
- Treatment: Brilinta · AstraZeneca
- Treatment: Brilinta · AstraZeneca
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing